RT Journal Article
SR Electronic
T1 COX 2-selective NSAIDs: Biology, promises, and concerns
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 285
OP 292
VO 66
IS 5
A2 Vidt, Donald G.
A1 Mandell, Brian F.
YR 1999
UL http://www.ccjm.org/content/66/5/285.abstract
AB Celecoxib (Celebrex) is the first of a new family of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit cydooxygenase 2 (COX 2) while sparing COX 1. Clinical trials indicate that it is approximately as effective in relieving the pain of osteoarthritis and the pain and inflammation of rheumatoid arthritis as nonselective NSAIDs, but causes less gastrointestinal ulceration and bleeding. This paper reviews the pharmacology and possible clinical role of celecoxib and other COX 2-selective NSAIDs.